The Sobi partnership validates lacutamab's commercial potential and provides a clear path to a confirmatory Phase 3 trial (TELLOMAK-3) and potential accelerated approval in Sézary syndrome. The €30m equity raise at €1.70/share adds dilution (17.6m new shares, ~19% of pre-offer shares) but was necessary to bridge to the Sobi upfront. Monitor for initiation of TELLOMAK-3 and any further pipeline updates on IPH4502.
Price Chart
Executive Summary
Innate Pharma's H1 2026 6-K reports a net loss of €19.6m (improved from €21.3m in H1 2025) on revenue of €5.7m (up from €4.9m), with cash burn reducing operating cash outflow to €21.0m. Critically, the filing discloses that as of June 30, 2026, the company lacked sufficient resources to fund 12 months of operations, but subsequent post-period events—a Sobi licensing deal for lacutamab (USD 75m upfront) and a €30m equity private placement—have extended the cash runway into Q1 2028, removing the immediate going-concern risk highlighted in the prior 20-F.
Key Facts
- Net loss of €19.6m in H1 2026 vs €21.3m in H1 2025; operating loss improved to €19.0m from €25.4m.
- Revenue and other income of €5.7m (H1 2025: €4.9m), driven by €3.1m collaboration/licensing revenue and €2.5m research tax credit.
- Cash, cash equivalents and financial assets fell to €21.4m as of June 30, 2026 from €44.8m at Dec 31, 2025; net cash was €0.1m.
- As of June 30, 2026, the company would not have had sufficient resources to fund 12 months of operations.
- Post-period: On Aug 10, 2026, entered a licensing/commercialization agreement with Sobi for lacutamab, with USD 75m upfront payment (conditions satisfied).
- Post-period: On Aug 14, 2026, completed a €30m private placement of 17,647,059 ordinary shares at €1.70/share.
- Management now expects sufficient funding into Q1 2028, removing the going-concern uncertainty.
- R&D expenses decreased 17.8% to €16.9m; headcount reduced from 174 to 120 FTE due to restructuring.
- Collaboration debt to AstraZeneca for monalizumab stood at €39.6m.
Financial Impact
The Sobi deal (USD 75m upfront) and €30m equity raise together provide ~€100m in new cash, extending runway to Q1 2028. The H1 2026 cash burn of €21.0m is lower than H1 2025's €31.2m, reflecting cost-cutting.
Risk Factors
- Dilution from the €30m private placement (17.6m new shares at €1.70).
- Execution risk on the TELLOMAK-3 confirmatory trial for lacutamab.
- Dependence on Sobi partnership for lacutamab commercialization; milestone payments are contingent.
- Continued net losses and reliance on partnership/equity financing for future operations.
- Large collaboration debt of €39.6m to AstraZeneca for monalizumab.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001598599-26-000010 |
| Document: inpha-20260630.htm | 0001598599-26-000010 |
| Document: 0001598599-26-000010-index-headers.html | 0001598599-26-000010 |
| Document: 0001598599-26-000010-index.html | 0001598599-26-000010 |
| Document: 0001598599-26-000010.txt | 0001598599-26-000010 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.57 | awaiting T+20 | — | $1.46 (−7.01%) |
Oct 20, 2026 6d ago | 6-K | $1.58 | awaiting T+20 | — | $1.46 (−7.48%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 17, 2026 5w ago | 6-K | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 16, 2026 5w ago | Press Release | $1.91 $1.48 | ▼ −22.51% | ▼ −23.97% | $1.46 (−23.56%) |
Sep 10, 2026 6w ago | 6-K | $1.88 $1.48 | ▼ −21.28% | ▼ −23.40% | $1.46 (−22.34%) |
Sep 2, 2026 7w ago | 6-K | $2.17 $1.63 | ▼ −24.88% | ▼ −24.80% | $1.46 (−32.72%) |
Aug 14, 2026 10w ago | 6-K | $2.18 $1.85 | ▼ −15.14% | ▼ −13.15% | $1.46 (−33.03%) |
Aug 10, 2026 11w ago | 6-K | $2.22 $2.05 | ▼ −7.66% | ▼ −6.74% | $1.46 (−34.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers